Surgical treatment of distant metastases of cutaneous melanoma

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

This article addresses the issue of surgical treatment effectiveness in cases of disseminated melanoma. It is shown that disseminated melanoma can be divided into truly disseminated and oligometastatic processes, where distant metastases are resectable. Previously, surgical intervention was the treatment of choice for patients with resectable distant metastases, however, with the development of new therapeutic approaches, such as immune checkpoint inhibitors and targeted therapies, the role of surgery has become less straightforward. However, tumor burden reduction through surgical removal of metastatic lesions may enhance the immune response. Combined treatment, involving surgical intervention and systemic therapy, has emerged as a new approach in treatment of disseminated melanoma, improving efficacy and prognosis. The article emphasizes the need for further research to determine the optimal approach for treatment in this patient population.

About the authors

Alexander A. Telegin

N.N. Blokhin National Medical Research Center of Oncology; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: dock996@bk.ru
ORCID iD: 0009-0009-1826-8850
SPIN-code: 9139-2916
Russian Federation, Moscow; Moscow

Evgeny V. Prozorenko

N.N. Blokhin National Medical Research Center of Oncology; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: prozorenko_e_v@staff.sechenov.ru
ORCID iD: 0000-0001-8880-1758
SPIN-code: 1177-8997

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow; Moscow

Igor V. Samoylenko

N.N. Blokhin National Medical Research Center of Oncology

Email: i.samoylenko@ronc.ru
ORCID iD: 0000-0001-7150-5071
SPIN-code: 3691-8923

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

Nadezhda V. Sevyan

N.N. Blokhin National Medical Research Center of Oncology; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: sevyan_n_v@staff.sechenov.ru
ORCID iD: 0000-0001-5841-7480
SPIN-code: 1404-7422

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow; Moscow

References

  1. Beckham TH, Yang TJ, Gomez D, et al. Metastasis-directed therapy for oligometastasis and beyond. Br J Cancer. 2021;124(1):136–141. doi: 10.1038/s41416-020-01128-5
  2. AlGhamdi H, Dhont J, Krayem M, et al. The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease. Cancers (Basel). 2022;14(8):2046. doi: 10.3390/cancers14082046
  3. Leung AM, Hari DM, Morton DL. Surgery for Distant Melanoma Metastasis. Cancer J. 2012;18(2):176–184. doi: 10.1097/PPO.0b013e31824bc981
  4. Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–65. doi: 10.1038/nature22079
  5. Steininger J, Gellrich FF, Schulz A, et al. Systemic Therapy of Metastatic Melanoma: On the Road to Cure. Cancers. 2021;13(6):1430. doi: 10.3390/cancers13061430
  6. Long GV, Grob J-J, Nathan P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016;17(12):1743–1754. doi: 10.1016/S1470-2045(16)30578-2
  7. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–1823. doi: 10.1056/NEJMoa1708539
  8. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–1835. doi: 10.1056/NEJMoa1709030
  9. Rose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg. 2001;136(8):950–955. doi: 10.1001/archsurg.136.8.950
  10. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181(3):193–201.
  11. Ollila DW, Hsueh EC, Stern SL, et al. Metastasectomy for recurrent stage IV melanoma. J Surg Oncol. 1999;71(4):209–213. doi: 10.1002/(sici)1096-9098(199908)71:4<209::aid-jso1>3.0.co;2-2
  12. Wasif N, Bagaria SP, Ray P, et al. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011;104(2):111–115. doi: 10.1002/jso.21903
  13. Orlova KV, Ledin E, Zhukova NV, et al. The role of surgery (metastasectomy) in advanced BRAF positive melanoma during modern therapy. Journal of Clinical Oncology. 2022;40:e21512–e21512. doi: 10.1200/JCO.2022.40.16_suppl.e21512
  14. Atkins MB, Lee SJ, Chmielowski B, et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. Randomized Controlled Trial. J Clin Oncol. 2023;41(2):186–197. doi: 10.1200/JCO.22.01763
  15. Olbryt M. Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy-Present State and Perspectives. Cancers (Basel). 2022;14(9):2315. doi: 10.3390/cancers14092315
  16. Amaral T, Seeber O, Mersi E, et al. Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma. Cancers (Basel). 2020;12(4):1027. doi: 10.3390/cancers12041027
  17. Prozorenko EV, Glushakov RI, Karakhan VB, et al. Cerebral metastases as a cause of non — traumatic intracranial hemorrhage: long-term results of surgical treatment. Military medical journal. 2020;341(8):46–53. EDN: ATIAUC
  18. Prozorenko E, Karahan V, Bekyashev A, et al. Hemorrhagic cerebral metastasis of melanoma and soft tissue sarcomas: surgical treatment and its results. Sarkomy kostei, myagkikh tkanei i opukholi kozhi. 2015;(3):3–7. EDN: VWZWJF

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).